Drug Use Study With Intuniv® in European Countries

Shire5,000 enrolled

Overview

This study will evaluate and characterize people who are taking Intuniv, analyze prescribing behaviors of physicians, and determine whether Intuniv was correctly prescribed in Belgium, Denmark, Finland, Germany, Ireland, Netherlands, Norway, Spain, Sweden, and the United Kingdom.

The study aims to characterize participants who are prescribed Intuniv® and describe prescribing patterns of Intuniv® among physicians in European countries. This study will collect data from the following sources: * Physician Survey: de-identified patient data provided by representative physicians in Belgium, Finland, Ireland, and the Netherlands, with a goal of data from up to 100 participants per survey wave. * Database Survey: longitudinal patient-level prescription database in all other countries with data on approximately 5000 participants. In the database study, actual prescription data are collected from electronic medical records and national registries. A prescriber survey will be conducted to evaluate health care professionals (HCPs) real-life practice. It will include data collection from the prescriber's (physician's) files and a web questionnaire, including de-identified data from up to 100 participants per survey wave.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

No InterventionOTHER

This is an observational study utilizing historical de-identified patient level data; therefore no intervention is given.

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Prescribers of Intuniv®, i.e. physicians who know and have prescribed the drug at least once during the previous 12 months (or, for the first report, since country specific launch) (paediatricians, psychiatrists, neurologists and GPs). * Participants who have been prescribed Intuniv® at least once during the reporting period. Exclusion Criteria: • Physicians who do not treat participants or who may have a conflict of interest (i.e. physicians employed by regulatory bodies or pharmaceutical industries).

Locations (1)

Real World Insights EMEA IQVIA Commercial GmbH & Co. OHG

Munich, Bavaria, Germany

Outcomes

Primary Outcomes

Number of Participants Stratified by Prescriber Information Based on Physician Survey

Participants will be stratified based on prescriber information which include demographics, specialty, and setting of prescriber.

Time frame: Up to 4 years

Number of Participants Categorised Based on Their Demographic Characteristics

The demographic characteristics will include age and gender.

Time frame: Up to 4 years

Number of Participants with Co-morbidities

Time frame: Up to 4 years

Number of Participants Based on Indication of Use of Prescribed Intuniv®

Indication of use (diagnosis) will be assessed as per World Health Organization (WHO) 10th International Statistical Classification of Diseases and Related Health Problems (ICD) classification.

Time frame: Up to 4 years

Number of Participants With ADHD Categorised Based on Different Patterns of Intuniv® Use

Patterns of drug use include first time users, repeat users, participants who discontinued the ADHD therapy, participants with switches in treatment (both from Intuniv® to other ADHD medications and other ADHD medications to Intuniv®), and participants with dosing/overdose (defined as daily dose of \>7 mg or of \>4mg in participants ≤12 years of age).

Time frame: Up to 4 years

Number of Participants Using Intuniv® as Second Line Treatment After Psychostimulant Prescription at any Time Prior to the Participant's First Prescription of Intuniv®

Time frame: Up to 4 years

Secondary Outcomes

Number of Physician Visits During the First Year of Therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.